Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery
Open Access
- 1 January 2011
- journal article
- research article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 43 (4) , 409-13
Abstract
Context: Nanotechnology is an empowering technology that holds promise in cancer therapeutics by increasing the ratio of tumor control probability to normal tissue complication probability. It can increase the bioavailability of the drug at the target site, reduce the frequency of administration and reach otherwise lesser-accessible sites. The present study shows the feasibility of the cisplatin-loaded albumin nanoparticle as a sustained delivery system. Aims: Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of malignant disorders. Conventional cisplatin formulation given as intravenous infusion has low bioavailability to the target organ in addition to significant side-effects, like ototoxicity and nephrotoxicity. The aim of this study was to develop a protein-based nanoparticulate system for sustained release of cisplatin. Materials and Methods: Nanoparticles were prepared by the coacervaton method of microcapsulation and chemical cross-linking with glutaraldehyde. Particle size was characterized by dynamic light scattering and transmission electron microscopy. Results and Conclusions: Using the coacervation method, nanoparticles of less than 70 nm diameter were produced. Drug encapsulation measured by ultraviolet spectroscopy varied from 30% to 80% for different ratios of cisplatin and protein. In vitro release kinetics shows that the nanoparticle-based formulation has biphasic release kinetics and is capable of sustained release compared with the free drug (80% release in 45 h). The study proves the feasibility of the albumin-based cisplatin nanoparticle formulation as a sustained release vehicle of cisplatin.Keywords
This publication has 24 references indexed in Scilit:
- Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatinExpert Opinion on Investigational Drugs, 2009
- The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalationBiomaterials, 2009
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticlesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rateEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC statusAnti-Cancer Drugs, 2008
- Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenograftsAnti-Cancer Drugs, 2008
- Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing miceJournal of Controlled Release, 2008
- Characterization of cisplatin cytotoxicity delivered from PLGA-systemsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Direct visualization and quantification of the anticancer agent, cis ‐diamminedichloro‐platinum(II), in human lung cancer cells using in‐air microparticle‐induced X‐ray emission analysisCancer Science, 2008